The overall goal of this study is to understand the immune response (IgG) to SARS-CoV-2 to fill critical knowledge gaps in the natural history of this virus and to inform the development of future infection mitigation efforts. The study team aims to assess the prevalence of circulating IgG antibodies to SARS-CoV-2 and the factors associated with sero-prevalence. These data will be used to estimate the total population that has been exposed to the virus (asymptomatic and symptomatic), the proportion of the population that may be protected by natural immunity, and the proportion that is susceptible. Data obtained from this research will be shared with the Florida Department of Health.
Diagnostic Test: SARS-CoV-2 Antibody Analysis
10 ml of blood will be drawn for antibody analysis. Participants who test SARCS-CoV-2 positive will be invited to participate in follow-up antibody testing at 4 weeks and at 3 months.
Diagnostic Test: Weck-cel Swab Collection
A Weck-cel swab will be used to collect secretions from the mucosal epithelium
Behavioral: Web Based Questionnaire
A brief web enabled questionnaire will be administered to collect information related to demographics, SARS-CoV-2 exposure history, past symptoms, comorbidities associates with increased infection and disease risk, as well as immunosuppression status and use to immunosuppressive medications.
Inclusion Criteria:
- Resident of Hillsborough County, Florida
- 18 years of age or older
- Currently not exhibiting symptoms of SARS-CoV-2 infection
Moffitt Cancer Center
Tampa, Florida, United States
Anna R Giuliano, PhD, Principal Investigator
Moffitt Cancer Center